Investor Relations

Company Overview

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Stock Information

Letter to Shareholders

Shareholder Letter (March 2024)

Recent Event

BIO International Convention

IR Contacts


MAIA Biotechnology, Inc.
444 West Lake Street
Suite 1700
Chicago, IL 60606
T: 312-416-8592

Investor Relations

T: 872-270-3518

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.